Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 1 14Phase 3 7Phase 1/2 3Phase NA 2Phase EARLY_PHASE1 1

Status

Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Ovarian Neoplasms 12Small Cell Lung Carcinoma 8Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Neoplasms 4Neuroblastoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia 3Fallopian Tube Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Thrombocytopenia 1Solid Tumors 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1SCLC, Extensive Stage 1Recurrence 1Radiation Injuries 1Primary Myelofibrosis 1Polycythemia Vera 1Peritoneal Neoplasms 1Myoepithelioma 1Myeloproliferative Disorders 1Multiple Myeloma 1Liposarcoma, Myxoid 1

Interventions

Temozolomide 10Irinotecan 8Cyclophosphamide 7dinutuximab 5aldesleukin 4Interleukin-2 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3fludarabine 3Topotecan 3Melphalan 3Isotretinoin 3Filgrastim 3gallium Ga 68 dotatate 2Vincristine 2TPI-287 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Carboplatin 2venetoclax 1trametinib 1thymoglobulin 1talazoparib 1sonidegib 1silmitasertib 1plerixafor 1olaparib 1naxitamab 1lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroblastoma × Topotecan × Clear all
NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
76 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT07334301 2026-01-12

BEACON2

University of Birmingham

Phase 1/2 Recruiting
160 enrolled
CNS

Neuroblastoma

NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Hoffmann-La Roche

Phase 1/2 Terminated
38 enrolled 34 charts
CNSLymphoidOther hematologic neoplasm

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡